This web site was copied prior to January 20, 2005. It is now a Federal record managed by the National Archives and Records Administration. External links, forms, and search boxes may not function within this collection. Learn more.   [hide]
skipnavHome|Search|Browse|Resources|Help|What's New|About

Urokinase-plasminogen activator (uPA) inhibitor WX-UK1 in combination with Capecitabine in Advanced Malignancies

This study is currently recruiting patients.

Sponsored by: Wilex
Information provided by: Wilex


The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.

Condition Treatment or Intervention Phase
Advanced malignancies
 Drug: WX-UK1 in combination with Capecitabine
Phase I

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study

Further Study Details: 

Expected Total Enrollment:  33

Study start: May 2004


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


Inclusion Criteria:

Exclusion Criteria:

Location and Contact Information

      Fox Chase Cancer Center, Philadelphia,  Pennsylvania,  19111,  United States; Recruiting
Lori Goldstein, Dr.  215-728-2191 
Lori Goldstein, Dr.,  Principal Investigator

More Information

Study ID Numbers:  WX/50-005
Record last reviewed:  May 2004
Record first received:  May 25, 2004 Identifier:  NCT00083525
Health Authority: United States: Food and Drug Administration processed this record on 2004-11-09
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act